The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending the approval of Sarclisa (isatuximab-irfc) in combination with bortezomib, lenalidomide, and dexamethasone, also called VRd, for the induction treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant. A final decision is expected in the coming months.
The Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for Cabometyx (cabozantinib) for adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.
